Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

한국어

ST PHARM CO., LTD.

에스티팜237690KOSDAQSector: Pharma & Biotech
₩103,0002.09%Market cap ₩2.15TAs of Sep 1, 2026 close · updated once daily
Market cap
₩2.15T
#37 in KOSDAQ
39.1x
Sector median 16.3x (profitable cos.)
3.62x
Sector median 1.61x
0.4%
Sector median 0.0%
A
Grade A67.8 ptsTop 15% of 2,523 graded stocksMethodology v2.0

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band A with a total score of 67.8 points.

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩84,700High ₩168,700
Latest close
Price change by period
1W
3.40%
1M
16.30%
3M
20.40%
1Y
10.90%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

75.6/100
How much debt does it carry relative to equity?
32.0%
Sector median 51.6%
Sector lowhighTop 30.2% in sector
Can it cover what's due within a year?
226.2%
Sector median 191.7%
Sector lowhighTop 42.7% in sector
How much of revenue becomes profit?
16.6%
Sector median -2.4%
Sector lowhighTop 10% in sector
How much did it earn on its own capital?
9.3%
Sector median -4.5%
Sector lowhighTop 14.8% in sector

Source filing: annual report (consolidated) — view original

2

Growth momentum

80.6/100
How much did revenue grow in a year?
21.2%
Sector median 6.4%
Sector lowhighTop 23% in sector
Has it grown steadily over three years?
10.0%
Sector median 4.9%
Sector lowhighTop 33.2% in sector
Did core profits grow in a year?
98.4%
Sector median 3.6%
Sector lowhighTop 13.6% in sector
Are core profits higher than three years ago?
207.7%
Sector median 3.5%
Sector lowhighTop 7.8% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original

3

Price attractiveness

48.2/100
Is the price expensive relative to earnings?
39.1x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 33.4% in sector
Is the price expensive relative to book value?
3.62x
Sector median 1.61x
Sector lowhighBottom 29.8% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis78.1/100
Does the company actually pay dividends?
0.4%
Sector median 0.0%
Sector lowhighTop 21.9% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025)
₩10.1B
Cash payout ratio, consolidated (FY2025)
18.3%

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 6 met · 3 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩55B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩14B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
5.1% → 7.6%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩14B vs ₩55B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
30.3% → 24.2%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
247.7% → 226.2%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
20,152,888 → 20,701,684
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
10.1% → 16.6%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.41x → 0.46x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original

Grade change history

Jul 23, 2026A

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Corporate value-up plan filed

Filed a “기업가치제고계획(자율공시)” (corporate value-up plan, voluntary disclosure) (filed 2025-09-30). View filing

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source
Periodic report filedMay 15, 2026Source

View in the filings calendar →